Cargando…
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice
New treatment strategies are urgently needed for glioblastoma (GBM)—a tumor resistant to standard-of-care treatment with a high risk of recurrence and extremely poor prognosis. Based on their intrinsic tumor tropism, adoptively applied mesenchymal stem cells (MSCs) can be harnessed to deliver the th...
Autores principales: | Kitzberger, Carolin, Shehzad, Khuram, Morath, Volker, Spellerberg, Rebekka, Ranke, Julius, Steiger, Katja, Kälin, Roland E., Multhoff, Gabriele, Eiber, Matthias, Schilling, Franz, Glass, Rainer, Weber, Wolfgang A., Wagner, Ernst, Nelson, Peter J., Spitzweg, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493263/ https://www.ncbi.nlm.nih.gov/pubmed/37701849 http://dx.doi.org/10.1016/j.omto.2023.08.004 |
Ejemplares similares
-
Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma
por: Spellerberg, Rebekka, et al.
Publicado: (2022) -
Selective sodium iodide symporter (NIS) genetherapy of glioblastoma mediatedby EGFR-targeted lipopolyplexes
por: Spellerberg, Rebekka, et al.
Publicado: (2021) -
The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy
por: Kitzberger, Carolin, et al.
Publicado: (2022) -
Taking Advantage of the TGFB1 Biology in Differentiated Thyroid Cancer to Stimulate Sodium Iodide Symporter (NIS)-Mediated Iodide Uptake in Engineered Mesenchymal Stem Cells
por: Han, Yang, et al.
Publicado: (2021) -
OR14-05 Taking Advantage Of The Interleukin-6-Biology In Differentiated Thyroid Cancer To Stimulate Sodium Iodide Symporter (NIS)-mediated Iodide Uptake In Engineered Mesenchymal Stem Cells
por: Florentine Koehler, Viktoria, et al.
Publicado: (2023)